Innovating Works

NGN-PET

Financiado
Modelling Neuron Glia Networks into a drug discovery platform for Pain Efficacio...
Modelling Neuron Glia Networks into a drug discovery platform for Pain Efficacious Treatments Sofia ref. 116072 Chronic Neuropathic Pain is frequently associated with peripheral nerve injury or disease. Peripheral injury activates both neuronal and glial components of the peripheral and central cellular circuitry. While it is widely known t... Chronic Neuropathic Pain is frequently associated with peripheral nerve injury or disease. Peripheral injury activates both neuronal and glial components of the peripheral and central cellular circuitry. While it is widely known that the subsequently altered interactions between neurons and glial cells contribute to pain development and to its chronification, the underlying mechanisms are poorly understood. Developing mechanism-based therapies targeting neuron-glial interactions to treat chronic pain will be crucial for improving the quality of life of many patients. Hence the development of novel therapeutic solutions represents a major challenge that demands a multi-disciplinary approach to decipher and understand pathological mechanisms and to translate them into predictive tools for drug development. The NGN-PET consortium addresses this challenge by forming a highly interdisciplinary team that builds upon expertise in areas of academic research on pain mechanisms, industrial knowhow on human stem cell-based tool development, HTS technologies and drug discovery. To achieve its goal we will develop preclinical model systems and assays which recapitulate the human in vivo situation and which can be interrogated for the identification, validation of molecular targets and the development new treatments. A focus of the project will be chemotherapy induced NP and the interplay between nociceptors, microglia and Schwann cells. NGN-PET will carefully characterize rodent in vivo and in vitro models to identify these mechanisms, and will develop rat and human iPSCs based in vitro systems of neuron-glial co-cultures that can be interrogated for targets and used for compound identification and validation. NGN-PET will thus pose the basis for the translation of these model systems into high throughput screening platforms for pharmaceutical research and drug discovery. ver más
31/03/2020
AXXAM
3M€
Duración del proyecto: 35 meses Fecha Inicio: 2017-04-26
Fecha Fin: 2020-03-31

Línea de financiación: concedida

El organismo H2020 notifico la concesión del proyecto el día 2020-03-31
Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:
IMI2-2015-07-03: PATHOLOGICAL NEURON-GLIA INTERACTIONS IN NEUROPATHIC PAIN
Cerrada hace 8 años
Presupuesto El presupuesto total del proyecto asciende a 3M€
Líder del proyecto
AXXAM SPA No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico TRL 4-5